Site navigation

Manus Neurodynamica Secures £600k for Cognitive Impairment Research

Ross Kelly


Manus Neurodynamica

The funding boost from Innovate UK will be used to optimise and validate Manus’ NeuroMotor Pen

Manus Neurodynamica, a developer of technologies for neuromotor assessment, has received £600,000 grant funding.

The funding boost from Innovate UK will be used to optimise and validate Manus’ NeuroMotor Pen product as part of a project over the next two years.

Manus’ NeuroMotor Pen aids health practitioners in the screening of dementia and cognitive impairment.

Over the next two years, Manus will carry out the project to optimise and validate NMP for screening of dementias.

The main objectives cover a breadth of areas, the company revealed, from fine tuning existing signal processing algorithms to extract digital biomarkers for Alzheimer’s dementia (AD), to completing clinical validation in 200 patients with early AD.

The project will also span data pipeline optimisation, inclusion of other clinical data points and rating scales for integration with NMP biomarkers, along with preparing for clinical deployment and creating budget impact analysis of NMP implementation in the early identification of AD.

Manus said it will engage with 100 citizens living with AD and their supporters to determine the usability and acceptability of NMP in the referral and diagnosis of dementia, its management and its suitability for remote assessment.

Commenting on the grant funding Manus CEO Rutger Zietsma said: “We are extremely pleased to be working at the forefront of this technology, aiming to provide results at primary care level, to help streamline the care pathway and ensure all patients will receive a timely diagnosis and supported earlier to develop long-term cognition and positive mental habits.

“This two-year project will help determine and validate the NMP for screening of dementias, as we set to roll-out our NMP later this year, initially applied in diagnosing Parkinson’s in the UK and Benelux markets, while also progressing work to secure regulatory approval to start selling in US.”


Only around 68% of over 65s, estimated to have dementia have been diagnosed. Early identification can hugely increase the chance of maintaining functional abilities and defer the point of escalation, where additional care and support is required at home or in a care facility.

Manus believes its NMP could play a crucial role in catching the early stages of the disease.

The handheld device with sensor technologies with decision support software enables users to non-invasively record and analyse parameters of minute limb and hand motion during drawing and writing movements.

These parameters are used as ‘digital biomarkers’ to provide objective information about decline in cognition and motor skill with higher accuracy than clinical ratings scales with electronic record keeping.

Ross Kelly

Staff Writer

Latest News

%d bloggers like this: